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Abstract
Background: Patients with prior coronary artery bypass graft (CABG) surgery often require percuta-
neous coronary intervention (PCI). Data are still limited in regards to the outcomes of native saphenous 
vein graft (SVG) PCI after CABG.
Methods: We performed a retrospective study in a tertiary reference cardiac center of consecutive pa-
tients who underwent PCI after CABG. The data were collected for patients who underwent either native 
or graft PCI from January 2008 to December 2018. Arterial graft PCIs were excluded. Multivariable 
Cox regression analysis with propensity matching was performed, and major adverse cardiac events 
(MACE) outcomes including death or myocardial infarction (MI) or revascularization were assessed 
at 1-year after each index procedure.
Results: A total of 435 PCI were performed in 401 patients (209 had native PCI and 192 had graft 
PCI). Target lesions were classified as following: 235 (54%) native coronary arteries and 200 (46%) 
SVG. Propensity matching resulted in 167 matched pairs. In multivariable Cox regression graft PCI 
relative to native PCI was an independent risk factor for MACE (hazard ratio [HR] 1.725, 95% 
confidence interval [CI] 1.049–2.837) which was primarily driven by increased incidence in revascu-
larization (HR 2.218, 95% CI 1.193–4.122) and MI (HR 2.248, 95% CI 1.220–4.142) and with no 
significant difference in mortality (HR 1.118, 95% CI 0.435–2.870).
Conclusions: Compared with native coronary PCI, bypass graft PCI was significantly associated with 
higher incidence of MACE at 1-year and this was mainly driven by MI and revascularization. (Cardiol 
J )
Key words: acute coronary syndrome, coronary artery bypass graft, coronary artery 
disease, major adverse cardiac event, percutaneous coronary intervention
Introduction
Patients with prior coronary artery bypass 
graft (CABG) surgery often require repeat revas-
cularization either due to graft failure or a combi-
nation of graft failure and progression of coronary 
atherosclerosis. Thrombosis, intimal hyperplasia 
and atherosclerosis are the main pathological pro-
cesses underlying saphenous venous grafts disease 
[1]. Early thrombosis is the principle cause of vein 
graft attrition during the first month after bypass 
surgery, with intimal hyperplasia being an issue 
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during the remainder of the first year. Thereafter, 
atherogenesis predominates. The optimal revas-
cularization strategy of patients with prior CABG 
and graft failure remains a subject of debate. Redo 
surgeries are associated with higher morbidity and 
mortality as well as poorer outcomes compared to 
initial operations [2]. Furthermore, there is limited 
evidence on the optimal percutaneous coronary in-
tervention (PCI) option (i.e. native coronary artery 
or graft PCI) in such population. Present study was 
conducted to compare 1-year major adverse cardiac 
events (MACE) of native versus graft PCI. 
Methods
This is a retrospective study performed in 
a tertiary cardiac center of CABG patients who 
underwent subsequent PCI. The data were col-
lected for consecutive patients who underwent 
either native or graft PCI from January 2008 to 
December 2018. Arterial graft PCI patients were 
excluded from the study. The procedural data for 
the patients who underwent PCI were collected 
from our local catheterization laboratory database. 
If a patient had more than one procedure during the 
study period, the first PCI was considered as the 
index procedure and the subsequent procedures 
were considered as outcomes. If a patient had 
undergone more than one PCI in the same first 
procedure during the study time period, all lesions 
intervened on underwent analysis. However, if 
those PCI involved both native and saphenous vein 
graft (SVG) interventions, then the patient was 
included in the SVG PCI study arm. The primary 
end point was 1-year MACE defined as a composite 
of death, myocardial infarction (MI) or target vessel 
revascularization. Secondary endpoints included 
angiographic complications (no-reflow, dissection 
and perforation). Patients’ mortality was identified 
from the hospital clinical system which is updated 
regularly from the United Kingdom’s Office of 
National Statistics. All outcomes were assessed 
at 1-year after each index procedure.
Statistical analysis
Continuous variables are presented as means 
(SD) or medians (IQR). For normally distributed 
variables, Student’s t-test was used, whereas in 
samples with non-normal distribution Mann–Whit-
ney U test was used. Categorical variables were 
compared with the use of Fisher’s exact tests 
(2-sided). To best control for the non-random as-
signment of patients to 1 of 2 PCI approaches, we 
have used a combination of matching methods: it 
is matched exactly on the categorical variables 
(gender, diabetes, chronic kidney disease, hyper-
tension, urgency of procedures and clinical presen-
tation [angina or acute coronary syndrome; ACS]) 
and used a propensity score on the age variable. 
So, in each matched pair the age may vary slightly 
but the other covariates all take exactly the same 
value. Matching resulted in 167 matched pairs. 
Kaplan–Meier curves for outcomes and compared 
with the use of the log-rank test. For multivariable 
analysis, the Cox regression model was applied. 
Estimated hazard ratios (HR) and their 95% con-
fident intervals (CI) were calculated. Two-sided 
statistics were performed with a p-value less than 
0.05 determining significance. Statistical analysis 
was performed using SPSS v.25.0 (IBM Corp., 
Armonk, New York, United States).
Results
A total of 435 PCI were performed to 401 
patients during the study period. They were clas-
sified as following: native coronary artery (235 
[54%]), SVG (200 [46%]), The native vessel and 
SVG intervention had comparable baseline char-
acteristics, left ventricular ejection fraction and 
clinical presentation (angina and ACS) as shown 
in Table 1. Graft age was greater in patients who 
underwent graft PCI. Femoral access was used in 
over half of both groups with no statistical differ-
ence between two groups. Most bypass graft target 
lesions were located at the body of the graft 58.6%. 
Compared with patients who underwent bypass 
graft PCI, those who underwent native coronary 
artery PCI were more likely to undergo PCI of 
a chronic total occlusion (CTO) or to an in-stent 
restenosis (ISR). In native vessel PCI, there was 
a greater likelihood of requiring more than one 
stent. However, in graft PCI stent diameters 
were larger. Regarding the length of the stents, 
there was no statistical difference between the 
two groups. In comparison to native coronary le-
sions, graft lesions were more likely to be treated 
with bare-metal stents (BMS) and drug eluting 
balloon. Patients in native PCI group were more 
likely to have post-procedural Thrombolysis in 
Myocardial Infarction III flow. Statistically, there 
was no difference in fluoroscopy time and contrast 
amount between both groups (Table 2). No reflow 
phenomenon was significantly more frequent in 
patients undergoing graft PCI compared to patients 
with native artery PCI (10% vs. 0.4%, p < 0.001) 
(Table 3). Matched groups analysis resulted in 
a significant difference in age between both groups 
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Table 1. Baseline characteristics and presentation of patients undergoing native and graft percutaneous 
coronary intervention, before and after matching.











Age, median (IQR) 70 [62–76] 70 [65–78] 0.090 71 [63–76] 71 [66–79] 0.023
Female 28 (13%) 29 (15%) 0.669 23 (14%) 23 (14%) 1
Comorbidities
Diabetes 84 (40%) 77 (40%) 1 67 (40%) 67 (40%) 1
Hypertension 148 (71%) 123 (64%) 0.166 112 (67%) 112 (67%) 1
Hyperlipidemia 99 (47%) 87 (45%) 0.690 78 (47%) 80 (48%) 0.913
Chronic kidney disease 30 (14%) 28 (15%) 1 23 (14%) 23 (14%) 1
Dialysis 3 (1%) 4 (2%) 0.714 3 (2%) 4 (2%) 1
Previous MI 156 (75%) 130 (68%) 0.151 122 (73%) 113 (68%) 0.338
Previous PCI 53 (25%) 47 (25%) 0.908 40 (24%) 40 (24%) 1
Reduced left ventricular 
systolic function  
(LVEF ≤ 40%)
60 (29%) 45 (23%) 0.256 50 (30%) 36 (22%) 0.103
Years from CABG,  
median (IQR)
10 [7–14] 12 [9–15] 0.002 10 [7–14] 12 [9–15] 0.003
Presentation
Urgent procedure 102 (49%) 116 (60%) 0.021 97 (58%) 97 (58%) 1
Angina 106 (51%) 76 (40%) 0.061 70 (42%) 70 (42%) 0.899
NSTEMI 66 (32%) 80 (42%) 63 (38%) 66 (40%)
STEMI 37 (18%) 36 (19%) 34 (20%) 31 (19%)
CABG — coronary artery bypass graft; IQR — interquartile range; LVEF — left ventricular ejection fraction; MI — myocardial infarction;  
NSTEMI — non-ST-segment elevation myocardial infarction; PCI — percutaneous coronary intervention; STEMI — ST-segment elevation 
myocardial infarction; SVG — saphenous vein graft
Table 2. Lesion characteristics and procedural details, before and after matching.










Femoral access 121 (52%) 111 (56%) 0.441 93 (49%) 97 (55%) 0.295
Targeted vessel
LM 28 (12%) – – 25 (13%) – –
LAD/diagonal 45 (19%) 48 (24%) 37 (20%) 42 (24%)
LCX/OM 76 (32%) 83 (42%) 59 (31%) 76 (42%)
RCA/PDA/PLV 86 (37%) 69 (33%) 68 (36%) 58 (33%)
Lesion characteristic
In-stent restenosis 26 (11%) 12 (6%) 0.087 18 (10%) 11 (6%) 0.245
True bifurcation 5 (1%) – – 5 (3%) 0 –
Graft aortic anastomosis – 63 (31.5%) – – 58 (33%) –
Graft body – 119 (59.5%) – 102 (58%) –
Graft distal anastomosis – 18 (9.0%) – – 16 (9%) –
Æ
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(p = 0.023), however the size of the difference was 
not large (median age 71 [63–76] vs. 71 [66–79] in 
native PCI and SVG PCI groups, respectively). On 
the other hand, after matching the presentation 
(stable angina or ACS) was equally distributed 
across the two groups. The lesion characteristics 
of matched patient groups were comparable to 
those prior to matching. Patients who underwent 
graft PCI had a significantly higher incidence of 
MACE (Fig. 1), principally driven by MI (Fig. 2) 
Table 2 (cont.). Lesion characteristics and procedural details, before and after matching.










Stents characteristics and TIMI flow
Number of stents,  
median (IQR)
1 [1–2] 1 [1–1] < 0.001 1 [1–2] 1 [1–1] < 0.001
Length of stents [mm], 
median (IQR)
23 [16–32] 22 [16–28] 0.114 23.5 [17–32] 22 [16–28] 0.138
Diameter of stents [mm], 
median (IQR)
3 [2.75–3.5] 3.5 [3.0–4.0] < 0.001 3.0 [2.75–3.5] 3.5 [3.0–4.0] < 0.001
Bare metal stents 22 (10%) 42 (20%) < 0.001 15 (8%) 37 (21%) < 0.001
Drug eluting stents 201 (87%) 138 (69%) 164 (88%) 121 (69%)
Drug eluting balloons 9 (4%) 19 (10%) 7 (4%) 17 (10%)
Pre-procedural TIMI flow
TIMI III flow 165 (70%) 135 (68%) 0.136 129 (68%) 120 (68%) 0.154
TIMI II flow 20 (9%) 14 (7%) 18 (10%) 10 (6%)
TIMI I flow 7 (3%) 16 (8%) 7 (4%) 15 (9%)
TIMI 0 flow 43 (18%) 35 (18%) 35 (19%) 31 (18%)
Post-procedural TIMI flow
TIMI III flow 233 (99%) 179 (90%) < 0.001 187 (99%) 157 (89%) < 0.001
TIMI II flow 1 (0.4%) 7 (4%) 1 (0.5%) 7 (4%)
TIMI I flow 1 (0.4%) 6 (3%) 1 (0.5%) 5 (3%)
TIMI 0 flow 0 8 (4%) 0 7 (4%)
Contrast amount,  
median (IQR) [mL]
230 [170–320] 230 [160–310] 0.643 230 [175–320] 230 [160–300] 0.422
Fluoroscopy time,  
median (IQR) [min]
16.5 [11–25] 16.5 [11–24.5] 0.824 17.5 [11.5–25.75] 18 [11–26] 0.951
IQR — interquartile range; PCI — percutaneous coronary intervention; SVG — saphenous vein graft; TIMI — Thrombolysis in Myocardial  
Infarction
Table 3. Peri-procedural complications before and after matching.










No reflow 1 (0.4%) 19 (10%) < 0.001 1 (0.5%) 16 (9%) < 0.001
Dissection 7 (3%) 2 (1%) 0.188 6 (3%) 2 (1%) 0.286
Perforation 3 (1%) 0 – 2 (1%) 0 –
Intra-aortic balloon pump 6 (3%) 3 (2%) 0.337 6 (3%) 3 (2%) 0.505
PCI — percutaneous coronary intervention; SVG — saphenous vein graft
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and revascularization rate (Fig. 3), while there was 
no significant difference in mortality (Fig. 4).
In multivariable Cox regression analysis (Ta-
ble 4) the only factor associated with MACE was 
graft PCI compared to native PCI (HR 1.725, 95% 
CI 1.049–2.837, p = 0.032). Age, urgency of the 
procedure, history of MI, diabetes, hypertension, 
hyperlipidemia, previous PCI, left ventricular ejec-
tion fraction, contrast amount used and fluoroscopy 
time were not significantly associated with MACE. 
Detailed Cox regression analyses on mortality, MI 
and revascularization are presented in Tables 5–7, 
respectively.
Discussion
This single-center study which compares out-
comes of PCI in patients with previous CABG has 
a number of interesting findings. Although there 
was no statistical difference in the baseline demo-
graphics of the two patient groups (Table 1), SVG 
PCIs were more likely to be urgent procedures. 
To reduce selection bias, there was a preponder-
ance of males in the present study (86%). There 
was an even greater disproportion as reported by 
Brilakis et al. (99% of males) [3]. This significant 
underrepresentation of females with prior CABG 
Figure 4. Mortality after index percutaneous coronary 
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Figure 1. Myocardial infarction or revascularization or 
death after index percutaneous coronary intervention 
(PCI) in matched groups.
Figure 2. Myocardial infarction after index percutaneous 
coronary intervention (PCI) in matched groups.
Figure 3. Revascularization after index percutaneous 
coronary intervention (PCI) in matched groups.
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Table 4. Multivariate Cox regression with regard to major adverse cardiac events in matched groups.
Parameter Hazard ratio 95% CI P
Age [years] 0.990 0.964–1.017 0.467
Type of procedure (urgent vs. elective) 0.913 0.551–1.513 0.724
Graft PCI vs. native PCI 1.725 1.049–2.837 0.032
History of MI 1.444 0.759–2.746 0.263
Previous PCI 1.677 0.966–2.912 0.066
Diabetes 0.972 0.536–1.761 0.925
Hypertension 1.440 0.728–2.847 0.294
Hyperlipidemia 1.240 0.713–2.157 0.446
Chronic kidney disease 1.403 0.741–2.656 0.299
Fluoroscopy time (1 min increase) 0.999 0.983–1.015 0.878
Contrast amount (1 mL increase) 1.001 0.999–1.004 0.254
LVEF (≤ 40%) 0.839 0.465–1.516 0.562
CI — confidence interval; MI — myocardial infarction; LVEF — left ventricular ejection fraction; PCI — percutaneous coronary intervention
Table 5. Multivariate Cox regression with regard to revascularization in matched groups.
Parameter Hazard ratio 95% CI P
Age [years] 0.964 0.933–0.995 0.025
Type of procedure (urgent vs. elective) 0.684 0.374–1.252 0.218
Graft PCI vs. native PCI 2.218 1.193–4.122 0.012
History of MI 1.650 0.737–3.691 0.223
Previous PCI 1.824 0.953–3.493 0.070
Diabetes 0.972 0.581–2.487 0.925
Hypertension 1.003 0.453–2.222 0.994
Hyperlipidemia 0.994 0.498–1.983 0.986
Chronic kidney disease 1.257 0.741–2.656 0.582
Fluoroscopy time (1 min increase) 0.998 0.977–1.020 0.867
Contrast amount (1 mL increase) 1.000 0.997–1.004 0.853
LVEF (≤ 40%) 0.953 0.472–1.923 0.893
CI — confidence interval; MI — myocardial infarction; LVEF — left ventricular ejection fraction; PCI — percutaneous coronary intervention
Table 6. Multivariate Cox regression with regard to myocardial infarction in matched groups.
Parameter Hazard ratio 95% CI P
Age [years] 0.996 0.964–1.028 0.791
Type of procedure (urgent vs. elective) 1.349 0.715–2.544 0.355
Graft PCI vs. native PCI 2.248 1.220–4.142 0.009
History of MI 1.226 0.600–2.506 0.576
Previous PCI 1.425 0.732–2.772 0.297
Diabetes 0.910 0.455–1.821 0.790
Hypertension 2.112 0.913–4.883 0.081
Hyperlipidemia 0.885 0.472–1.656 0.701
Chronic kidney disease 1.667 0.804–3.454 0.169
Fluoroscopy time (1 min increase) 1.001 0.984–1.018 0.924
Contrast amount (1 mL increase) 1.001 0.998–1.004 0.413
LVEF (≤ 40%) 1.152 0.593–2.238 0.675
CI — confidence interval; MI — myocardial infarction; LVEF — left ventricular ejection fraction; PCI — percutaneous coronary intervention
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in need of subsequent PCI reported in studies to 
date warrants further prospective assessment. 
In the current study there was a relatively high 
percentage of radial approach (47%) in comparison 
to the other reported studies [4]. RADIAL-CABG 
Trial [5] was a randomized prospective study 
which suggested that diagnostic angiography us-
ing radial access compared with femoral access 
was associated with greater contrast use, longer 
procedure and fluoroscopy time as well as greater 
patient and operator radiation exposure. However, 
no significant differences in these parameters 
were observed among patients undergoing PCI in 
the present study. Other studies suggested that 
a radial approach is feasible and is as fast as the 
femoral approach [6, 7]. It was noted that venous 
grafts were more likely to be the PCI target vessel 
with increasing time after CABG, consistent with 
the accelerated pace of late saphenous venous 
graft failure [8]. Nearly all target bypass grafts 
were SVG, a reflection of the excellent outcomes 
achieved with use of internal mammary arteries 
[9, 10]. Radial-artery grafts have a lower rate of 
graft occlusion at 1-year than SVGs [11]. We would 
thus advocate a randomized study to compare the 
outcomes of conventional CABG versus a hybrid 
approach where only arterial grafts would be used, 
plus PCI for the other vessels. It was found that 
patients who underwent bypass graft rather than 
native coronary PCI were more likely to receive 
BMS. The benefits of drug eluting stents (DES) 
over BMS in venous graft interventions are still 
controversial. The DIVA study [12], which is the 
most recent randomized trial included 597 patients 
undergoing PCI of de-novo SVG lesions. There was 
no significant difference in 12-month and long-term 
(median 2.7 years) incidence of cardiac death, target 
vessel MI or target vessel revascularization (TVR). 
DES implantation was associated with improved 
results in ISAR-CABG trial which randomized 610 
patients with diseased SVG to DES or BMS and 
reported that DES were associated with favorable 
hard endpoint outcomes (15.4% vs. 22.1%; p = 
0.03) [13]. The stenting of saphenous vein grafts 
trial (SOS), also demonstrated a significant reduc-
tion in MACE rates with paclitaxel-eluting stents 
compared with BMS, which was mainly driven by 
lower target lesion revascularization (TLR) rates 
[14]. Sirolimus-eluting stents were studied in the 
Reduction of Restenosis In Saphenous Vein Grafts 
With Cypher Sirolimus-eluting Stent RRISC trial 
[15], which demonstrated a reduction in TLR and 
TVR, and late stent loss in the DES group com-
pared with the BMS group at 6 months. Conversely, 
the DELAYED RRISC study [16] found the TVR 
benefit was lost at 3-year follow-up and BMS was 
associated with lower long-term mortality. In the 
present study, no-reflow was significantly higher 
in graft PCI compared to native artery PCI (10% 
vs. 0.4%; p < 0.001). Venous graft PCI was an 
independent risk factor for the peri-procedural 
complications including no-reflow [17], especially 
if the presentation was ST-segment elevation MI 
[18]. From our real-world data, SVG PCI carried 
a higher risk of MACE at 1 year when compared 
with native coronary PCI, that was mainly driven 
by MI and TVR. All of the efforts need to be taken 
into consideration to attempt native coronary 
revascularization. Percutaneous revascularization 
of CTO continues to gain popularity and accept-
Table 7. Multivariate Cox regression with regard to mortality in matched groups.
Parameter Hazard ratio 95% CI P
Age [years] 1.047 0.990–1.107 0.107
Type of procedure (urgent vs. elective) 0.684 0.537–5.495 0.361
Graft PCI vs. native PCI 1.118 0.435–2.870 0.817
History of MI 1.327 0.403–4.370 0.642
Previous PCI 0.913 0.282–2.954 0.879
Diabetes 0.900 0.303–2.674 0.850
Hypertension 4.859 0.564–4.829 0.150
Hyperlipidemia 1.942 0.660–5.719 0.228
Chronic kidney disease 2.296. 0.809–6.513 0.118
Fluoroscopy time (1 min increase) 1.005 0.983–1.028 0.642
Contrast amount (1 mL increase) 1.004 1.000–1.008 0.060
LVEF (≤ 40%) 0.840 0.262–2.694 0.769
CI — confidence interval; MI — myocardial infarction; LVEF — left ventricular ejection fraction; PCI — percutaneous coronary intervention
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ance despite its risk and complexity. Techniques 
have improved with the increasing availability 
of new equipment as previous studies showed 
favorably high success rates for CTO PCI even 
in previously bypassed patients [19–21]. SVG can 
be used to attempt CTO PCI via the retrograde 
approach as shown in a previous study [22]. Ana-
tomic complexity in patients with previous CABG 
might adversely impact in the outcome of chronic 
coronary occlusions PCI [23]. Redo CABG carries 
a higher mortality rate compared with first-time 
CABG [24, 25]. In post-CABG patients, PCI was 
associated with better survival compared to redo 
CABG [26]. Another study suggested no difference 
in survival between redo CABG and PCI, however, 
PCI was associated with a higher revascularization 
rate [27]. Overall, redo CABG could be considered 
as an option for revascularization especially if the 
arterial graft (i.e. left anterior mammary artery; 
LIMA) was not used during the first CABG.
Limitations of the study
Firstly, it was a retrospective study and not 
a prospective randomized trial and hence was sub-
ject to all the limitations of observational studies. 
Secondly, the choice of PCI target was dependent 
on the judgement of the operator. Thirdly, some 
patient data may have been missed since not all 
patients were routinely followed up at 12 months 
post-procedure.
Conclusions
The present study findings would currently 
support considering PCI in the native vessel rather 
than the failing venous graft in patients with previ-
ous CABG. Further work however is needed and, 
in this respect, the currently ongoing PROCTOR 
study, a multi-center, prospective trial is randomiz-
ing patients to native vessel versus venous graft 
PCI [28].
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